title: An ADP-ribosyltransferase as a potential target for nitric oxide action in hippocampal long-term potentiation.
abstract: Recent studies of long-term potentiation (LTP) in the CA1 region of the hippocampus have demonstrated that nitric oxide (NO) may be involved in some forms of LTP and have suggested that postsynaptically generated NO is a candidate to act as a retrograde messenger. However, the molecular target(s) of NO in LTP remain to be elucidated. The present study examined whether either of two potential NO targets, a soluble guanylyl cyclase or an ADP-ribosyltransferase (ADPRT; EC 2.4.2.31) plays a role in LTP. The application of membrane-permeant analogs of cGMP did not produce any long-lasting alterations in synaptic strength. In addition, application of a cGMP-dependent protein kinase inhibitor did not prevent LTP. We found that the CA1 tissue from hippocampus possesses an ADPRT activity that is dramatically stimulated by NO and attenuated by two different inhibitors of mono-ADPRT activity, phylloquinone and nicotinamide. The extracellular application of these same inhibitors prevented LTP. Postsynaptic injection of nicotinamide failed to attenuate LTP, suggesting that the critical site of ADPRT activity resides at a nonpostsynaptic locus. These results suggest that ADP-ribosylation plays a role in LTP and are consistent with the idea that an ADPRT may be a target of NO action.
authors.affiliation: Department of Molecular and Cellular Physiology, Stanford University School of Medicine, CA 94305-5426.
authors.forename: E M
authors.initials: EM
authors.lastname: Schuman
authors.forename: M K
authors.initials: MK
authors.lastname: Meffert
authors.forename: H
authors.initials: H
authors.lastname: Schulman
authors.forename: D V
authors.initials: DV
authors.lastname: Madison
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000818:Animals; D006152:Cyclic GMP / Q000502:physiology; D003995:Dibutyryl Cyclic GMP / Q000494:pharmacology; D005071:Evoked Potentials / Q000187:drug effects / Q000502:physiology; D006624:Hippocampus / Q000187:drug effects / Q000502:physiology*; D066298:In Vitro Techniques; D017774:Long-Term Potentiation / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008981:Molsidomine / Q000031:analogs & derivatives / Q000494:pharmacology; D016202:N-Methylaspartate / Q000494:pharmacology; D009243:NAD / Q000378:metabolism; D009536:Niacinamide / Q000494:pharmacology; D009569:Nitric Oxide / Q000502:physiology*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism*; D017966:Pyramidal Cells / Q000187:drug effects / Q000201:enzymology / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D014665:Vasodilator Agents; D009243:NAD; D009536:Niacinamide; D009569:Nitric Oxide; D003995:Dibutyryl Cyclic GMP; C002385:linsidomine; D016202:N-Methylaspartate; D015763:2-Amino-5-phosphonovalerate; D008981:Molsidomine; D011065:Poly(ADP-ribose) Polymerases; D006152:Cyclic GMP